Focus


Focus on Tuberculosis

In what direction is the field of tuberculosis going? By bringing together input from top scientists, analysts and decision makers interested in tuberculosis research, this focus identifies the recent papers with the most impact in the discipline and identifies the key issues that are shaping our thinking in this field.

Top

Editorial

Tuberculosis

Tuberculosis p263

doi:10.1038/nm0307-263


Top

News




Tuberculosis

News feature: A clash of cultures pp268 - 270

Apoorva Mandavilli

doi:10.1038/nm0307-268



Tuberculosis

Spotlight on... Mark Harrington p270

Alisa Opar

doi:10.1038/nm0307-270



Tuberculosis

Spotlight on... Ken Duncan p271

Alisa Opar

doi:10.1038/nm0307-271b


Tuberculosis

News feature: Trials and tribulations pp272 - 273

Apoorva Mandavilli

doi:10.1038/nm0307-272


Tuberculosis

Spotlight on... Mario Raviglione p273

Brandon Keim

doi:10.1038/nm0307-273



Tuberculosis

When the vaccine causes disease p274

Apoorva Mandavilli

doi:10.1038/nm0307-274b


Tuberculosis

Profile: Wafaa El-Sadr p275

Apoorva Mandavilli

doi:10.1038/nm0307-275


Top

Analysis


Tuberculosis

Highly cited papers on tuberculosis (2003–2005) p278

doi:10.1038/nm0307-278


Top

News and Views

Tuberculosis

The open book of infectious diseases pp279 - 280

Christopher M Sassetti & Eric J Rubin

doi:10.1038/nm0307-279


Tuberculosis

Defining the 'survivasome' of Mycobacterium tuberculosis pp280 - 282

Gyanu Lamichhane & William Bishai

doi:10.1038/nm0307-280


Tuberculosis

The survival kit of Mycobacterium tuberculosis pp282 - 284

Digby F Warner & Valerie Mizrahi

doi:10.1038/nm0307-282


Tuberculosis

Mycobacterium tuberculosis virulence: lipids inside and out pp284 - 285

Sabine Ehrt & Dirk Schnappinger

doi:10.1038/nm0307-284




Top

Commentaries

Tuberculosis

Challenges in tuberculosis drug research and development pp290 - 294

Ann M Ginsberg & Melvin Spigelman

doi:10.1038/nm0307-290


Tuberculosis

From magic bullets back to the Magic Mountain: the rise of extensively drug-resistant tuberculosis pp295 - 298

Susan E Dorman & Richard E Chaisson

doi:10.1038/nm0307-295


Tuberculosis

Changing funding patterns in tuberculosis pp299 - 303

Stefan H E Kaufmann & Shreemanta K Parida

doi:10.1038/nm0307-299


Tuberculosis

Aligning pharmaceutical innovation with medical need pp304 - 308

Carl Nathan

doi:10.1038/nm0307-304


Top

Market Analysis

Tuberculosis

Tuberculosis, a neglected opportunity? pp309 - 312

Claire Harper

doi:10.1038/nm0307-309


Top